Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 3
2005 1
2006 1
2008 1
2011 1
2012 3
2013 1
2019 1
2021 1
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Time-Driven Activity-Based Costing of CT-Guided vs MR-Guided Prostate SBRT.
Parikh NR, Clark MA, Patel P, Kafka-Peterson K, Zaide L, Ma TM, Steinberg ML, Cao M, Raldow AC, Lamb J, Kishan AU. Parikh NR, et al. Among authors: clark ma. Appl Radiat Oncol. 2021 Sep;10(3):33-40. Epub 2021 Oct 5. Appl Radiat Oncol. 2021. PMID: 34671700 Free PMC article.
Clinical adoption patterns of 0.35 Tesla MR-guided radiation therapy in Europe and Asia.
Slotman BJ, Clark MA, Özyar E, Kim M, Itami J, Tallet A, Debus J, Pfeffer R, Gentile P, Hama Y, Andratschke N, Riou O, Camilleri P, Belka C, Quivrin M, Kim B, Pedersen A, van Overeem Felter M, Kim YI, Kim JH, Fuss M, Valentini V. Slotman BJ, et al. Among authors: clark ma. Radiat Oncol. 2022 Aug 22;17(1):146. doi: 10.1186/s13014-022-02114-2. Radiat Oncol. 2022. PMID: 35996192 Free PMC article.
Patterns of utilization and clinical adoption of 0.35 Tesla MR-guided radiation therapy in the United States - Understanding the transition to adaptive, ultra-hypofractionated treatments.
Chuong MD, Clark MA, Henke LE, Kishan AU, Portelance L, Parikh PJ, Bassetti MF, Nagar H, Rosenberg SA, Mehta MP, Refaat T, Rineer JM, Smith A, Seung S, Zaki BI, Fuss M, Mak RH. Chuong MD, et al. Among authors: clark ma. Clin Transl Radiat Oncol. 2022 Nov 22;38:161-168. doi: 10.1016/j.ctro.2022.11.013. eCollection 2023 Jan. Clin Transl Radiat Oncol. 2022. PMID: 36466748 Free PMC article.
Drug-eluting stent task force: final report and recommendations of the working committees on cost-effectiveness/economics, access to care, and medicolegal issues.
Hodgson JM, Bottner RK, Klein LW, Walpole HT Jr, Cohen DJ, Cutlip DE, Fenninger RB, Firth BG, Greenberg D, Kalisky I, Meskan T, Powell W, Stone GW, Zito JP, Clark MA. Hodgson JM, et al. Among authors: clark ma. Catheter Cardiovasc Interv. 2004 May;62(1):1-17. doi: 10.1002/ccd.20025. Catheter Cardiovasc Interv. 2004. PMID: 15103593 Review.
Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
Bakhai A, Stone GW, Mahoney E, Lavelle TA, Shi C, Berezin RH, Lahue BJ, Clark MA, Lacey MJ, Russell ME, Ellis SG, Hermiller JB, Cox DA, Cohen DJ; TAXUS-IV Investigators. Bakhai A, et al. Among authors: clark ma. J Am Coll Cardiol. 2006 Jul 18;48(2):253-61. doi: 10.1016/j.jacc.2006.02.063. Epub 2006 Jun 22. J Am Coll Cardiol. 2006. PMID: 16843171 Free article.
17 results